Ironwood Pharmaceuticals Projects Strong Revenue Growth for 2026
Ironwood Pharmaceuticals forecasts revenue of $450-475M for 2026, driven by Linzess sales growth. Stock surges 28% on positive outlook and pipeline progress.
/ 3 items
#IRWD↓
FDA Greenlights Linaclotide (Linzess) for Children 7 Years and Older with Irritable Bowel Syndrome with Constipation
Ironwood's Linzess is the first FDA-approved drug for children 7+ with IBS-C (chronic constipation, pain, and bloating).
Ironwood Rises as AbbVie’s Linzess Sales Beat Expectations
Ironwood shares climb after AbbVie reports strong Q3 Linzess sales of $315M, surpassing estimates and boosting investor confidence.